Acrux Limited (FRA:FJY)
Germany flag Germany · Delayed Price · Currency is EUR
0.0070
0.00 (0.00%)
At close: Dec 5, 2025

Acrux Company Description

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally.

The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream.

It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain associated with chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores.

The company was incorporated in 1998 and is based in West Melbourne, Australia.

Acrux Limited
Country Australia
Founded 1998
Industry Pharmaceutical Preparations
Employees 43
CEO John Warmbrunn

Contact Details

Address:
103-113, Stanley Street
West Melbourne, Victoria 3003
Australia
Phone 61 3 8379 0100
Website acrux.com.au

Stock Details

Ticker Symbol FJY
Exchange Frankfurt Stock Exchange
Fiscal Year July - June
Reporting Currency AUD
SIC Code 2834

Key Executives

Name Position
John Warmbrunn Chief Executive Officer
Joanna Johnson Chief Financial Officer